News You Might Have Missed: Nov 28th 2022

The article News You Might Have Missed: Nov 28th 2022 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.

Awakn Life Sciences Announces Location for Larger Oslo Clinic

Awakn Clinics Oslo’s new location will be a 6-treatment room clinic situated near the center of Oslo and will replace the existing clinic. The new clinic will have increased capacity for treating clients and will also provide the potential to deliver research and clinical trials on site. The clinic is expected to finish the completion of renovations in early 2023 with the opening expected soon after that in Q2. The next stage in Awakn’s Nordic expansion is expected to be a clinic opening in Trondheim next year.

Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

“Clearmind continues its progress toward FIH clinical trial” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “This milestone joins other achievements we’ve made in a relatively short period.  Non-clinical data generated to date, demonstrate that our MEAI- based treatment has the potential to treat broad range of addictions and binge behaviors such as AUD.”

Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement

The Prospectus Supplement is  the second supplement  filed in connection with the Subscription Agreement and provides, among other things, that the Company is qualifying the distribution of up to 943,396 common shares in the capital of the Company to the Investor at  a price of $0.53 per Share for aggregate gross proceeds of up to $499,999.8

Awakn Life Sciences Announces Closing of Private Placement

Awakn has announced the closing of a second and final tranche of its previously announced non-brokered private placement through the issuance of an additional 3,395,812 units at a price of $0.55 per Unit for additional gross proceeds of $1,867,697. In total, including the first tranche, the company has issued 5,557,630 Units at $0.55 for a total value at $3,056,697.

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

Read More